Skip to Content
Merck
CN

Key Documents

View All Documentation

S4696

SB-505124 hydrochloride hydrate

≥98% (HPLC), activin receptor-like kinase (ALK) 5 inhibitor, powder

Synonym(s):

2-(5-Benzo[1,3]dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrochloride hydrate

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C20H21N3O2 · xHCl · yH2O
CAS Number:
694433-59-5
Molecular Weight:
335.40 (anhydrous free base basis)
UNSPSC Code:
12352200
PubChem Substance ID:
24724611
NACRES:
NA.77
MDL number:
MFCD11045901
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
100
Storage condition:
desiccated
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

SB-505124 hydrochloride hydrate, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

yellow

solubility

DMSO: >10 mg/mL, H2O: insoluble

originator

GlaxoSmithKline

storage temp.

2-8°C

SMILES string

O.Cl.Cc1cccc(n1)-c2[nH]c(nc2-c3ccc4OCOc4c3)C(C)(C)C

InChI

1S/C20H21N3O2.ClH.H2O/c1-12-6-5-7-14(21-12)18-17(22-19(23-18)20(2,3)4)13-8-9-15-16(10-13)25-11-24-15;;/h5-10H,11H2,1-4H3,(H,22,23);1H;1H2

InChI key

DIDCCMVWCVRTNB-UHFFFAOYSA-N

Application

SB-505124 hydrochloride hydrate was used to study the role of TGF-β pathway in development and differentiation studies.3,4

Biochem/physiol Actions

SB-505124 is an inhibitor of activin receptor-like kinase (ALK) 5, also known as transforming growth factor-α type I receptor kinase, with an IC50 of 47 ± 5 nM.
SB-505124 selectively inhibits TGF-β type I receptors, activin receptor-like kinases (ALK) 4, 5 and 7. It inhibits ALK4-, 5- and 7-mediated activation of Smad2, Smad3 and MAPK pathway induced by TGF-β.1 SB-505124 inhibits the human fibroblast trans-differentiation induced by the co-culture with Esophageal squamous cell carcinoma.2

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
034M4617V
041M4516V
041M4616V
050M46291
050M4629

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Stacey DaCosta Byfield et al.
Molecular pharmacology, 65(3), 744-752 (2004-02-24)
Clinically, there is a great need for small molecule inhibitors that could control pathogenic effects of transforming growth factor (TGF-beta) and/or modulate effects of TGF-beta in normal responses. Inhibition of TGF-beta signaling would be predicted to enhance re-epithelialization of cutaneous
Kazuhiro Noma et al.
Gastroenterology, 134(7), 1981-1993 (2008-04-29)
Esophageal squamous cell carcinoma (ESCC) is known to be a highly angiogenic tumor. Here, we investigated the role of the stromal fibroblasts in the ESCC-induced angiogenic response using a novel 3-dimensional model. A novel assay was developed where cocultures of
Mary C Trask et al.
Developmental biology, 368(2), 273-282 (2012-06-07)
The ubiquitously expressed Polycomb Group protein Yin-Yang1 (YY1) is believed to regulate gene expression through direct binding to DNA elements found in promoters or enhancers of target loci. Additionally, YY1 contains diverse domains that enable a plethora of protein-protein interactions
View All Related Papers

Global Trade Item Number

SKUGTIN
S4696-25MG04061832434230
S4696-5MG04061836928131